Month: November 2010

Tapping Molecular Pathology’s New Gold Mine

IN ONE SENSE, WE CAN SAY THAT THE DECADE OF 2001 THROUGH 2010 was bookended by two one-half billion dollar anatomic pathology acquisitions. Each transaction was a powerful signal to Wall Street investors. Unfortunately, most pathologists are not tuned into that signal and so continue to miss the message. It was back in 2002 when …

Tapping Molecular Pathology’s New Gold Mine Read More »

Sonic Makes Big Play In AP With CBL Path Buy

CEO SUMMARY: With the announcement that it will purchase CBL Path, Inc., Sonic Healthcare, Ltd., becomes the latest public laboratory company to buy a sizeable presence in the national anatomic pathology (AP) marketplace. For CBL Path, founded in 2003 by ex-Dianon executives and sales professionals, it is the exit strategy for which they have long …

Sonic Makes Big Play In AP With CBL Path Buy Read More »

GE Pulls Plug on Its LIS, No Support after July 2013

CEO SUMMARY: Not in recent memory has a laboratory information system (LIS) product been pulled from the market. That is why the announcement by GE Healthcare that it would no longer service or support its Centricity Ultra Laboratory product after July 23, 2013, has caused a stir within the healthcare informatics industry. In the United …

GE Pulls Plug on Its LIS, No Support after July 2013 Read More »

Several Laboratory Companies On Road to Public Stock Offering

ONE OF THE FEW PUBLIC STOCK OFFERINGS involving a lab testing company was completed last Wednesday. Exact Sciences, Inc., of Madison, Wisconsin sold $69 million worth of new shares to the public. Exact Sciences has proprietary diagnostic technology that it describes as “for noninvasive, molecular screening technology for the detection of colorectal cancer.” During 2009, …

Several Laboratory Companies On Road to Public Stock Offering Read More »

Whole Genome Sequencing: Is It Ready for Prime Time?

CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagnostic, therapeutic, and prognostic information they contain. GenomeQuest CEO Richard Resnick discusses what is required …

Whole Genome Sequencing: Is It Ready for Prime Time? Read More »

Aetna Sues LabCorp Over Lab Marketing Practices

CEO SUMMARY: Aetna, Inc., sued Laboratory Corporation of America in federal court, seeking injuctive relief for actions taken once LabCorp became an out-of-network laboratory provider for Aetna in July 2007. LabCorp is also accused of a “malicious scheme to continue to receive revenue” from Aetna. However, as an out-of-network laboratory provider, LabCorp has only been …

Aetna Sues LabCorp Over Lab Marketing Practices Read More »

Dark Daily

November 15, 2010 “Intelligence: Late Breaking Lab News”

During this last election, a pathologist ran for the U.S. Senate, but his campaign did not draw much attention within the lab testing community. Pathologist Eric Wargotz, M.D., was the Republican nominee for the U.S. Senate in Maryland. His opponent was Democratic Senator Barbara Mikulski, running for her fifth term. On election day, Mikulski outpolled …

November 15, 2010 “Intelligence: Late Breaking Lab News” Read More »